Another record year for Bayer –
good progress with the acquisition of Monsanto

  • Group sales €46.8 billion (Fx & portfolio adj. + 3.5%)
  • Substantial sales and earnings increases at Pharmaceuticals
  • Consumer Health grows with competition
  • Crop Science successful in a difficult market environment
  • EBITDA before special items €11.3 billion (+ 10.2%)
  • Net income €4.5 billion (+ 10.2%)
  • Core earnings per share €7.32 (+ 7.3%)
  • Operating cash flow €8.3 billion (+ 20.8%)
  • Forecast for 2017: further growth in sales and earnings

Sales1, 2

+ 3.5 %

EBITDA Before Special Items1

+ 10.2 %

Net Income1

+10.2%

Core Earnings per Share1

+ 7.3 %

Supplier Management3

98 % of all strategically important suppliers evaluated since 2012

Investment in
Research and Development

4.7 billion + 9.2% compared
with 2015

Specific Greenhouse Gas Emissions4

- 18 %  since 2012

Work-Related Accidents

- 7.1 %

Proportion of Women
in Senior Management

29 %

1 Change from 2015; 2015 figures restated
2 Currency- and portfolio-adjusted
3 Life Sciences
4 Life Sciences without Currenta

Latest Key Data

The interactive chart generator of Bayer AG gives an overview of the key financial and ecological data for the past five years. You can collate the given key data and years yourself in the form of tables, bar charts or line charts. Diagrams can be saved as graphics, tables as Excel documents.